[Ip-health] Oxfam submission to the WHO Draft Concept Note Concerning the General Programme of Work
mkamalyanni at Oxfam.org.uk
Fri Oct 13 11:20:33 PDT 2017
Oxfam comments to WHO 13th General Programme of Work
This document provides Oxfam comments on the Draft concept note towards
WHO’s 13th General Programme of Work 2019–2023 (GPW13) made available on
the WHO website Keep the World Safe, Improve Health, Serve the Vulnerable.
Draft Concept Note towards WHO’s 13th General Programme of Work 2019–2023
is available here: http://who.int/about/gpw-thirteen-consultation/en/
and open for comment from until Friday 13 October 2017. This is in
addition to the submission of Acton for Global Health.
Oxfam welcomes the new WHO DG prioritization of Universal Health Coverage
(UHC) and the right to health and the emphasis on the health of women and
marginalized groups in his first 100 days including at the 2017 United
National General Assembly and the WHO regional committees. We also welcome
the nomination of a diverse and competent new leadership team.
Oxfam appreciates the sharing of this concept note and the establishment
of a process for consultation and engagement in the development of the
13th WHO General Programme of Work.
This is an extremely important moment for WHO and for global health. It is
essential that this new General Programme of Work empowers not only WHO
but also governments, civil society, and the whole UN system to address
global health challenges and opportunities, as well as to adapt to be able
to respond to the commitments made in the Agenda 2030 Sustainable
Development Goals (SDGs) framework.
Oxfam would like to share the following general comments:
· Oxfam welcomes the priorities and directions outlined in the
concept note. There is close alignment among the five leadership
priorities, highlighting the strategic direction proposed, and the
assessment of needs that Oxfam witnesses throughout our work on health and
· The concept note needs stronger recognition of the global crisis
of innovation and access to medicines and the links between this crisis,
UHC and Agenda 2030 objectives of the Sustainable Development Goals. It
should reference the strategies needed to stop the rationing of essential
medical care due to high prices or lack of innovation in health
· As the concept note appropriately reflects, the world needs a
strong WHO. This requires Member States to appropriately resource WHO and
to enable the organization to have the authority to independently
implement its mandate - free from conflict of interest. This includes
providing data and technical guidance and convening to set up new norms.
WHO should also call on governments and non-governmental actors to amend
their policies that could have negative impact on public health.
· Oxfam agrees with the WHO recognition that some of the most
significant health “gains” originate in policies from sectors outside of
health and, thus, the notion that all the SDGs are health related. We
would like to suggest that the draft also recognize that the most
significant “threats and challenges” to health also originate from sectors
outside of health, such as the impact that intellectual property monopoly
protections pursued in trade agreements have on innovation and access to
medicines and other health technologies. It is therefore important for the
WHO work plan to set up a clear intersectoral work strategy and to
leverage the mandates and expertise within the UN system in order to adapt
the global health response to countries’ needs. For example, the WHO
should recognize and enable better responses at global and national levels
to the interdependence between health and trade, development, human rights
· It is essential that WHO maintain and strengthen its normative and
technical functions, which constitute a role that nobody else can play and
that has a huge impact at country-level. For example, there should be an
emphasis on the important role of the WHO in creating essential medicine
lists and on the pre-qualification programme for medicines, vaccines and
· It is important to highlight the critical value that WHO’s
convening role to develop global norms, conventions, regulations, and
frameworks has played and needs to continue playing. The Framework
Convention on Tobacco Control and the International Health Regulations
were landmark normative processes that WHO needs to continue its work in
implementing. Oxfam agrees with the comments of the government of India
(at the 70th SEARO regional committee meeting) that the time has come for
WHO to lead on the negotiations for a global Research and Development
(R&D) agreement which would provide global norms for funding R&D as a
public good, as recommended by many, including the WHO CEWG (Consultative
Expert Working Group on Research and Development: Financing and
Coordination) report and the UN Secretary General’s High Level Panel on
Access to Medicines.
· As the concept note recognizes, while it is important to set up
norms and strategic plans, it is vital to then ensure these are
implemented. WHO already has strong mandates that have yet to be funded
and implemented. For example, it is critical for the WHO to be able to
lead on the implementation of existing mandates like those included in the
WHO Global Strategy and Plan of Action on Public Health, Innovation and
Intellectual Property and the resolutions adopted to follow up from the
CEWG. WHO has not sufficiently prioritized the implementation of these
existing mandates, and therefore in its next work programme the WHO needs
to prioritize implementing plans and frameworks relevant to access to
medicines and innovation.
· Beyond the essential implementation and resourcing of existing WHO
mandates, WHO must go further. The 2030 Agenda for Sustainable Development
requires a broadening and adaptation of WHO mandates on access to
medicines and innovation in order to respond to the universality and
sustainability of the new goals.
A WHO work programme and strategy that responds to the 2030 Agenda for
Sustainable Development needs to:
· Recognize and address the challenge of lack of access to medicines
and innovation due to a broken innovation system. The challenge has now
become global as it affects UHC ambitions in all countries, irrespective
of their development or economic level.
§ Oxfam welcomes the creation of a cluster on essential medicines
and hopes that the increased attention and resources will ensure that WHO
plays its leading role in securing quality health technologies that are
available and affordable for all. WHO should ensure that any new cluster
addressing medicines, vaccines and diagnostics fully integrates R&D and
access into an integrated strategy.
§ WHO should provide normative and political assistance to all
countries to facilitate the use of the TRIPS flexibilities to promote
price-lowering competition and the creation of innovation policies that
can deliver a public return on public R&D investment.
§ WHO should expand its role in setting priorities and coordinating
health R&D for medicines, vaccines, diagnostics and other health
technologies, while ensuring that such medical tools are of assured
quality and are available, affordable and accessible for all. Efforts by
WHO to help R&D funders implement and increase policy coherence on R&D
norms and principles should be strengthened and prioritized – for example
through the work of the WHO CEWG, the WHO Blueprint for R&D for epidemics
and the global stewardship and development framework for antimicrobial
§ WHO should expand activities to improve transparency: High
medicine prices are often due to the pervasive secrecy surrounding health
technologies’ development costs. WHO can and should play a leading role to
expand transparency – building on successful efforts to expand clinical
trial data transparency as well as transparency of pricing, most notably
through the Vaccine Product, Price and Procurement (V3P) initiative. WHO
could do more to clearly outline the cost and investments for R&D, as well
as to expand efforts to improve patent, pricing and registration
o WHO should ensure that strategies address the unmet needs of all
those left behind, especially vulnerable populations, refugees and
internally displaced persons. Nearly 60 million people are currently
fleeing conflict or persecution around the world. Millions of refugees
face dangerous and often inhumane conditions without access to medical
care, while many others remain wholly excluded from existing health care
o As recognized in the synthesis report on the post-2015 development
agenda by the former United Nations Secretary-General Ban Ki-moon, there
is a need to address the challenges caused by the existing policy
incoherence in international, regional and domestic legal and policy
frameworks. Such incoherence has negative impacts on public health. For
example, governments’ obligations under human rights laws clash with their
adoption of the investor-state dispute settlement mechanism in trade
agreements that could stop governments from regulating inappropriate
marketing of products that can damage public health.
o There is a great need for WHO leadership to prioritize the
evaluation and implementation of the recommendations that are included in
the UN High Level Panel on Access to Medicines at the WHO, the UN and
other all other relevant forums.
o The achievement of the SDGs requires a high-level UN and
whole-of-government approach to Health and Equity, beyond the essential
role of Ministers of Health at the World Health Assembly. WHO needs to
work better with the whole UN system to promote policy coherence for
health and equity.
Best wishes مع أطيب التمنيات
Mohga -Dictating to the computer so please forgive silly mistakes
Dr. Mohga Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
Editor of www.globalhealthcheck.org
John Smith Drive, Oxford, OX4 2JY, UK (GMT, CET-1, EDT+5, EST+6)
UK Mobile + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni
Oxfam works with others to overcome poverty and suffering.
Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)
More information about the Ip-health